Literature DB >> 6811172

Combined hereditary deficiency of the sixth component of complement and factor VIII coagulant activity in a Dutch family.

M R Daha, R M Bertina, J Thompson, R H Kauffmann, A Nicholson-Weller, J J Veltkamp, E Briët.   

Abstract

Prompted by previous observations of defective blood clotting in rabbits deficient in the sixth component of complement (C6), and the discovery of a patient with both C6 and factor VIII deficiency, an evaluation was made of the haemostatic functions in this individual and his family members. The family contained three members homozygous for C6 deficiency (C6D); two of them were deficient also in factor VIII. In addition, one other member of the family was only deficient in factor VIII. The only C6D member without haemophilia A had a normal recalcification time without clinical symptoms of a bleeding disorder. Reconstitution of factor VIII and C6 deficient plasma from the various members of the family in this study with purified human C6 did not result in a change in the recalcification time. The results obtained from this study also indicate that there is no linkage between the inheritance of C6 and factor VIII.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6811172      PMCID: PMC1536627     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  15 in total

1.  Genetic independence between the HL--A system and deficits in the first and sixth components of complement.

Authors:  K K Mittal; K P Wolski; D Lim; A Gewurz; H Gewurz; F R Schmid
Journal:  Tissue Antigens       Date:  1976-02

Review 2.  Complement deficiency states.

Authors:  V Agnello
Journal:  Medicine (Baltimore)       Date:  1978-01       Impact factor: 1.889

3.  Detection of heterozygotes for recessive von Willebrand's disease by the assay of antihemophilic-factor-like antigen.

Authors:  J J Veltkamp; N H van Tilburg
Journal:  N Engl J Med       Date:  1973-10-25       Impact factor: 91.245

4.  Enhanced alternative complement pathway-dependent degradation of soluble immunoglobulin aggregates by macrophages.

Authors:  M R Daha; L A Van Es
Journal:  Immunology       Date:  1981-07       Impact factor: 7.397

5.  Neisseria meningitidis and Neisseria gonorrhoeae bacteremia associated with C6, C7, or C8 deficiency.

Authors:  B H Petersen; T J Lee; R Snyderman; G F Brooks
Journal:  Ann Intern Med       Date:  1979-06       Impact factor: 25.391

6.  Purification of the sixth and seventh component of human complement without loss of hemolytic activity.

Authors:  E R Podack; W P Kolb; H J Müller-Eberhard
Journal:  J Immunol       Date:  1976-02       Impact factor: 5.422

7.  C3 nephritic factor (C3NeF): stabilization of fluid phase and cell-bound alternative pathway convertase.

Authors:  M R Daha; D T Fearon; K F Austen
Journal:  J Immunol       Date:  1976-01       Impact factor: 5.422

8.  Human deficiency of the eighth component of complement. The requirement of C8 for serum Neisseria gonorrhoeae bactericidal activity.

Authors:  B H Petersen; J A Graham; G F Brooks
Journal:  J Clin Invest       Date:  1976-02       Impact factor: 14.808

9.  Hereditary C5 deficiency in man. III. Studies of hemostasis and platelet responses to zymosan.

Authors:  R T Breckenridge; S I Rosenfeld; K S Graff; J P Leddy
Journal:  J Immunol       Date:  1977-01       Impact factor: 5.422

10.  Simultaneous occurrence of hereditary C6 and C2 deficiency in a French-Canadian family.

Authors:  J M Delâge; G Lehner-Netsch; R Lafleur; J Simard; G Brun; E Prochazka
Journal:  Immunology       Date:  1979-06       Impact factor: 7.397

View more
  9 in total

1.  Functional deficiency of complement factor D in a monozygous twin.

Authors:  H C Kluin-Nelemans; H van Velzen-Blad; H P van Helden; M R Daha
Journal:  Clin Exp Immunol       Date:  1984-12       Impact factor: 4.330

2.  Functionally active complement proteins C6 and C7 detected in C6- and C7-deficient individuals.

Authors:  R Würzner; A Orren; P Potter; B P Morgan; D Ponard; P Späth; M Brai; M Schulze; L Happe; O Götze
Journal:  Clin Exp Immunol       Date:  1991-03       Impact factor: 4.330

3.  Protection against meningococcal serogroup ACYW disease in complement-deficient individuals vaccinated with the tetravalent meningococcal capsular polysaccharide vaccine.

Authors:  C A Fijen; E J Kuijper; M Drogari-Apiranthitou; Y Van Leeuwen; M R Daha; J Dankert
Journal:  Clin Exp Immunol       Date:  1998-12       Impact factor: 4.330

4.  Predictive value of IgG autoantibodies against C1q for nephritis in systemic lupus erythematosus.

Authors:  C E Siegert; M R Daha; C M Tseng; I E Coremans; L A van Es; F C Breedveld
Journal:  Ann Rheum Dis       Date:  1993-12       Impact factor: 19.103

5.  Diagnostic strategy for the assessment of rheumatoid vasculitis.

Authors:  A E Voskuyl; J M W Hazes; A H Zwinderman; E M Paleolog; F J M van der Meer; M R Daha; F C Breedveld
Journal:  Ann Rheum Dis       Date:  2003-05       Impact factor: 19.103

6.  Deficiency of complement component C3 is associated with accelerated removal of soluble 123I-labelled aggregates of IgG from the circulation.

Authors:  C Halma; M R Daha; J A Camps; J H Evers-Schouten; E K Pauwels; E s Van
Journal:  Clin Exp Immunol       Date:  1992-12       Impact factor: 4.330

7.  IgG autoantibodies to C1q do not detectably influence complement activation in vivo and in vitro in systemic lupus erythematosus.

Authors:  C E Siegert; M R Daha; S Lobatto; E A van der Voort; F C Breedveld
Journal:  Immunol Res       Date:  1992       Impact factor: 2.829

8.  Fulminant meningococcal septic shock in a boy with combined inherited properdin and protein C deficiency.

Authors:  C A Fijen; B H Derkx; E J Kuijper; M Mannens; S R Poort; M Peters; M R Daha; J Dankert
Journal:  Clin Exp Immunol       Date:  1995-11       Impact factor: 4.330

9.  Complete and partial deficiencies of complement factor D in a Dutch family.

Authors:  P S Hiemstra; E Langeler; B Compier; Y Keepers; P C Leijh; M T van den Barselaar; D Overbosch; M R Daha
Journal:  J Clin Invest       Date:  1989-12       Impact factor: 14.808

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.